ICOSAVAX INC (ICVX) Stock Price & Overview
NASDAQ:ICVX • US45114M1099
The current stock price of ICVX is 15.31 USD. Today ICVX is down by -0.91%. In the past month the price decreased by -0.78%. In the past year, price increased by 68.8%.
ICVX Key Statistics
- Market Cap
- 766.878M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.22
- Dividend Yield
- N/A
ICVX Stock Performance
ICVX Stock Chart
ICVX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ICVX. When comparing the yearly performance of all stocks, ICVX is one of the better performing stocks in the market, outperforming 94.46% of all stocks.
ICVX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ICVX. ICVX has a great financial health rating, but its profitability evaluates not so good.
ICVX Earnings
ICVX Forecast & Estimates
12 analysts have analysed ICVX and the average price target is 18.87 USD. This implies a price increase of 23.25% is expected in the next year compared to the current price of 15.31.
For the next year, analysts expect an EPS growth of 5.52% and a revenue growth -100% for ICVX
ICVX Groups
Sector & Classification
ICVX Financial Highlights
Over the last trailing twelve months ICVX reported a non-GAAP Earnings per Share(EPS) of -2.22. The EPS decreased by -1.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -38.48% | ||
| ROE | -41.61% | ||
| Debt/Equity | 0 |
ICVX Ownership
ICVX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.34 | 402.577B | ||
| AMGN | AMGEN INC | 16.55 | 203.574B | ||
| GILD | GILEAD SCIENCES INC | 16.52 | 181.247B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.4 | 125.079B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.57 | 81.897B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.95 | 42.495B | ||
| INSM | INSMED INC | N/A | 30.048B | ||
| BIIB | BIOGEN INC | 11.85 | 27.955B | ||
| NTRA | NATERA INC | N/A | 27.865B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.24 | 23.875B | ||
| MRNA | MODERNA INC | N/A | 22.105B | ||
| EXAS | EXACT SCIENCES CORP | 340.18 | 19.738B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.736B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ICVX
Company Profile
Icosavax, Inc. engages in the development and commercialization of vaccines against infectious diseases. The company is headquartered in Seattle, Washington and currently employs 60 full-time employees. The company went IPO on 2021-07-29. The firm uses its virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with a focus on life-threatening respiratory diseases. Its VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens. Its pipeline includes vaccine candidates targeting viral causes of pneumonia. The company is developing these candidates for older adults, a patient population with high unmet need. Its lead vaccine candidate, IVX-A12, is a bivalent candidate, or a mixture of two different VLP candidates. IVX-A12 combines IVX-121, a vaccine candidate designed to target respiratory syncytial virus (RSV), and IVX-241, a vaccine candidate designed to target human metapneumovirus (hMPV). The company is also developing additional vaccine candidates as part of its strategy to develop combination VLP vaccines targeting the viral causes of pneumonia in older adults, including influenza and SARS-CoV-2.
Company Info
IPO: 2021-07-29
ICOSAVAX INC
1930 Boren Ave., Suite 1000
Seattle WASHINGTON US
CEO: Adam Simpson
Employees: 60
Phone: 12067370085
ICOSAVAX INC / ICVX FAQ
What does ICOSAVAX INC do?
Icosavax, Inc. engages in the development and commercialization of vaccines against infectious diseases. The company is headquartered in Seattle, Washington and currently employs 60 full-time employees. The company went IPO on 2021-07-29. The firm uses its virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with a focus on life-threatening respiratory diseases. Its VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens. Its pipeline includes vaccine candidates targeting viral causes of pneumonia. The company is developing these candidates for older adults, a patient population with high unmet need. Its lead vaccine candidate, IVX-A12, is a bivalent candidate, or a mixture of two different VLP candidates. IVX-A12 combines IVX-121, a vaccine candidate designed to target respiratory syncytial virus (RSV), and IVX-241, a vaccine candidate designed to target human metapneumovirus (hMPV). The company is also developing additional vaccine candidates as part of its strategy to develop combination VLP vaccines targeting the viral causes of pneumonia in older adults, including influenza and SARS-CoV-2.
What is the current price of ICVX stock?
The current stock price of ICVX is 15.31 USD. The price decreased by -0.91% in the last trading session.
What is the dividend status of ICOSAVAX INC?
ICVX does not pay a dividend.
What is the ChartMill technical and fundamental rating of ICVX stock?
ICVX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of ICOSAVAX INC (ICVX) based on its PE ratio?
ICOSAVAX INC (ICVX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.22).
How many employees does ICOSAVAX INC have?
ICOSAVAX INC (ICVX) currently has 60 employees.